Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
“Werewolf continues to focus on the execution of our lead clinical programs WTX-124 and WTX-330, with updates planned for later in the second quarter.
- “Werewolf continues to focus on the execution of our lead clinical programs WTX-124 and WTX-330, with updates planned for later in the second quarter.
- Financial Results for the First Quarter of 2024:
Cash position: As of March 31, 2024, cash and cash equivalents were $139.2 million, compared to $134.3 million as of December 31, 2023. - General and administrative expenses: General and administrative expenses were $5.0 million for each of the first quarters of 2024 and 2023.
- Net loss: Net loss was $16.2 million for the first quarter of 2024, compared to $12.0 million for the same period in 2023.